{"id":474746,"date":"2026-02-17T23:36:34","date_gmt":"2026-02-17T23:36:34","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/474746\/"},"modified":"2026-02-17T23:36:34","modified_gmt":"2026-02-17T23:36:34","slug":"former-michigan-medicine-dean-omitted-pharma-ties-in-multiple-publications","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/474746\/","title":{"rendered":"Former Michigan Medicine dean omitted pharma ties in multiple publications"},"content":{"rendered":"

Over a decade marked by a pandemic and nationwide cuts<\/a> to health care funding, Marschall S. Runge led Michigan Medicine<\/a> in a historic triple-leadership position. He served as executive vice president of medical affairs and chief executive officer of Michigan Medicine starting in 2015. In 2016, he was appointed dean of the Medical School, serving in all three roles until 2025<\/a>.\u00a0<\/p>\n

The University of Michigan credits<\/a> Runge with doubling philanthropic funding and leading the University to its greatest growth in research advancement. In addition to his administrative roles, Runge conducted research<\/a> of his own, which was largely centered on cardiovascular topics.\u00a0<\/p>\n

His University responsibilities made him one of the institution\u2019s highest compensated<\/a> faculty. In 2024, he was the second-highest paid U-M employee with a salary surpassing $2.38 million<\/a>.<\/p>\n

Runge was on another payroll, too.\u00a0<\/p>\n

In 2013, Runge was elected to the board of directors<\/a> at pharmaceutical giant Eli Lilly<\/a>, where he served until August 2024<\/a>. Though Lilly is a known producer of at least one<\/a> cardiovascular drug, it is unclear whether the research Runge conducted is directly affiliated with the drugs Lilly manufactures.\u00a0<\/p>\n

Runge received at least $2 million from Lilly throughout his tenure as a board member according to Open Payments<\/a>, a government database that discloses physicians\u2019 external financial relationships.\u00a0<\/p>\n

It isn\u2019t uncommon<\/a> for doctors to receive compensation from drug and medical device companies for consulting for them. But, an investigation conducted by The Michigan Daily found the payments Runge received from Lilly far exceeded the amounts most of his peers at other hospitals accepted from similar companies, and that the level of outside compensation is not mirrored by Runge\u2019s U-M leadership<\/a> colleagues.\u00a0<\/p>\n

The Daily also found that Runge omitted his financial ties to Lilly in at least 12 of his journal publications. Two of these nondisclosures appeared in ScienceDirect<\/a>, which is owned by Elsevier<\/a>.\u00a0<\/p>\n

The Daily requested comment from Elsevier about whether the journal was aware of Runge\u2019s conflicts of interest at the time of publication. In a Dec. 5, 2025 email response to The Daily, Elsevier Communications Director Rebecca Clear wrote the company upholds the highest standards of ethics in its publishing to protect the quality and integrity of research.<\/p>\n

\u201cIn accordance with our commitment, this case is currently under investigation, and we cannot disclose further information until the investigation is complete,\u201d Clear wrote.\u00a0<\/p>\n

In a Jan. 20 corrigendum<\/a> to one of Runge\u2019s articles, Elsevier noted Runge\u2019s omission of his board of directors position at the time of the article\u2019s original<\/a> publication.\u00a0<\/p>\n

\u201cThe authors regret omitting to include that Marschall S. Runge was a member of the Board of Directors of Eli Lilly at the time of this publication and apologize for any inconvenience that resulted,\u201d the corrigendum read.\u00a0<\/p>\n

Runge declined The Daily\u2019s repeated requests for an interview. However, Runge provided a statement via Mary Masson, Michigan Medicine senior director of public relations, on Dec. 3, 2025. Runge stated that, during his time at the University, he adhered to all of its school-specific requirements.\u00a0<\/p>\n

\u201cI followed every aspect of the University of Michigan conflict of interest (COI) policy. This included receiving approval from the President and the Board of Regents to join the Lilly Board and providing annual updates on any issues that could pose a conflict,\u201d Runge wrote.<\/p>\n

The Daily could not confirm whether Runge\u2019s nondisclosures conflicted with University policies.\u00a0<\/p>\n

In an interview with The Daily, Dr. Eric Campbell, research director at the University of Colorado Anschutz Center for Bioethics and Humanities<\/a>, said that, while external financial relationships with drug and medical device manufacturing companies aren\u2019t necessarily abnormal, they may pose liabilities.\u00a0\u00a0<\/p>\n

\u201cWhen you get to serve on these boards, you can make quite a bit of money,\u201d Campbell said. \u201cIt could change the education. It could bias the research. And it also has the potential to leave the impression among the public, elected officials and even the employees that their leaders are essentially trading the reputation of the institution for their own personal benefit.\u201d<\/p>\n

While Open Payments data show Runge received more than $2 million from Lilly from 2018 to 2024, The Daily was unable to recover compensation numbers prior to 2018.<\/p>\n

Each year, more than 95% of Runge\u2019s received payments were categorized as \u201ccompensation for services other than consulting,\u201d a category that includes speaking, training and participating in educational engagements unrelated to continuing medical education.<\/p>\n

Runge also received compensation from Lilly in the form of stocks. In 2024, Lilly reported<\/a> that Runge owned thousands of combined shares and stock units in the company. Based on Lilly\u2019s current share price<\/a>, they\u2019re valued at more than $17 million.\u00a0<\/p>\n

An analysis by The Daily of the University Medical School\u2019s executive and senior leadership found Runge\u2019s colleagues at the University did not engage in similar financial relationships with pharmaceutical companies.\u00a0\u00a0\u00a0<\/p>\n

\"Bar<\/p>\n

An analysis by The Daily also found that Runge receives the second-highest external compensation among the deans of the top 20 medical schools<\/a> ranked by research.<\/p>\n

\"Chart<\/p>\n

In an interview with The Daily, Dr. Robert Steinbrook, Public Citizen<\/a> Health Research Group director, said the allegiances of leaders who participate in external financial relationships may be called into question.\u00a0<\/p>\n

\u201cA dean speaks on behalf of the institution, represents the institution and the question arises: \u2018What\u2019s the loyalty?\u2019\u201d Steinbrook said. \u201cIs the loyalty to the institution, or is the loyalty to the outside organization, whether it\u2019s a pharmaceutical company or somebody else?\u201d<\/p>\n

The industry standard for researchers who have financial ties is simple: disclose competing interests. Professionals far and wide caution<\/a> authors of research publications to err on the side of disclosure, with top<\/a> research institutions and journals maintaining this sentiment.\u00a0<\/p>\n

For conflict of interest disclosure policies, many peer-reviewed journals follow the standards outlined by the International Committee of Medical Journal Editors<\/a>. In a page dedicated to disclosure best practices, ICMJE posits that, while external relationships do not always indicate problematic influence on paper, perceptions of conflict may erode trust in science.\u00a0<\/p>\n

\u201cPublic trust in the scientific process and the credibility of published articles depend in part on how transparently an author\u2019s relationships and activities, directly or topically related to a work, are handled during the planning, implementation, writing, peer review, editing, and publication of scientific work,\u201d the ICMJE page reads.\u00a0<\/p>\n

At least<\/a> three<\/a> of<\/a> the journals in which Runge has been published explicitly utilize the ICMJE\u2019s guidelines in their own conflict of interest disclosure policies.\u00a0<\/p>\n

The University has long stood as a pioneer of medical research and innovation, ranking 12th in global research reputation according to the U.S. News & World Report rankings<\/a>. For U-M employees, the standards for disclosures are clearly defined by the Office of Research Ethics and Compliance<\/a>: any actual or potential conflicts of interest must be reviewed, eliminated or managed.\u00a0<\/p>\n

Runge sat on Lilly\u2019s board of directors for 11 years, advising its Ethics and Compliance and Science and Technology subcommittees. In that period, he authored 23 journal publications. In 12 of those papers, his financial ties to Lilly were omitted.<\/p>\n

Beginning in 2022, Runge began uniformly disclosing his ties to Lilly.\u00a0<\/p>\n

\"Pie<\/p>\n

It is unclear whether Runge\u2019s cardiovascular research is directly affiliated with the cardiovascular drug Lilly manufactures.\u00a0<\/p>\n

The Daily could not confirm whether Runge\u2019s omission of his financial relationship with Lilly in these journals violated U-M-specific conflict of interest disclosure standards for researchers. When asked to provide the Michigan Medicine conflict of interest policy, Masson wrote in a Feb. 4 email to The Daily that it is not publicly accessible.\u00a0<\/p>\n

In publications where Runge disclosed his ties to Lilly, there was an explicit statement establishing Runge\u2019s connection to the company.\u00a0<\/p>\n

\"Dr.<\/p>\n

\"Dr.<\/p>\n

\"Dr.<\/p>\n

In publications where Runge did not disclose his ties to Lilly, verbiage varied.<\/p>\n

\"Dr.<\/p>\n

\"Dr.<\/p>\n

\"Dr.<\/p>\n

\"Dr.<\/p>\n

\"Dr.<\/p>\n

\"Dr.<\/p>\n

Campbell also maintains that industry leaders, like Runge, should be prudent when deciding whether to disclose their financial ties.<\/p>\n

\u201cI firmly believe that, as leaders, they are not naive to this field,\u201d Campbell said. \u201cThey, more than anyone, should know the rules, and they, more than anyone, should be as conservative and as open in disclosure as they can be.\u201d<\/p>\n

Along with the ICMJE, all of the journals in which Runge is published had the same policy: Financial relationships must be disclosed.<\/p>\n

\"Conflict<\/p>\n

\"Conflict<\/p>\n

\"Conflict<\/p>\n

The Daily requested comment from all relevant journal publishers: Elsevier (ScienceDirect), The Journal of Clinical Investigation<\/a>, the American Heart Association<\/a>, Mary Ann Liebert (Sage<\/a>), National Institutes of Health<\/a> and Ovid<\/a>. Only Elsevier and JCI responded.\u00a0<\/p>\n

In a Jan. 23 email to The Daily, JCI Executive Editor Sarah Jackson wrote that, while she was not able to comment on a specific case, the journal relies on authors to identify any potential financial conflicts when they submit their manuscripts.\u00a0\u00a0<\/p>\n

\u201cIt is the responsibility of the corresponding author to collect the list of all potential conflicts from each author and to communicate it to the editors with the submission,\u201d Jackson wrote.\u00a0<\/p>\n

In addition to the article corrected by Elsevier, Runge omitted his financial ties to Lilly in at least one<\/a> other ScienceDirect publication.<\/p>\n

Elsevier has issued no other corrigenda.\u00a0<\/p>\n

After the creation of Open Payments as part of the Physician Payment Sunshine Act<\/a> under the Patient Protection and Affordable Care Act<\/a> \u2014 which was codified<\/a> in 2010 and requires manufacturers to report financial relationships with physicians and hospitals \u2014 high-ranking individuals<\/a> and institutions began receiving criticism<\/a> for not disclosing external financial conflicts of interest<\/a>.\u00a0<\/p>\n

As a result, medical and academic institutions began implementing conflict of interest disclosure policies to mitigate any appearances of impropriety.<\/p>\n

In 2012, the University followed suit, requiring researchers to follow<\/a> the Public Health Service regulations outlined in the Code of Federal Regulations<\/a>. The policy requires institutions receiving NIH funding to maintain an up-to-date, enforced policy that manages, reduces or eliminates a researcher\u2019s financial conflicts of interest.\u00a0<\/p>\n

In the statement provided by Runge, he wrote that he pioneered the rollout of the Michigan Medicine conflict of interest disclosure policies in compliance with national regulation.<\/p>\n

\u201cI abided by the COI policy and led the rollout of the policy to all of Michigan Medicine because I firmly believe it is essential to the honesty and integrity expectations of all faculty and staff,\u201d Runge wrote.\u00a0\u00a0<\/p>\n

It is unclear what the exact policy that Runge referenced contains, as Michigan Medicine\u2019s conflict of interest policy is not publicly available. But, an anonymous 2025 report given to The Daily alleges Runge\u2019s role in the policy carries a certain irony. The authors express concern that Runge\u2019s external financial ties directly conflict with the standards expected of faculty.\u00a0<\/p>\n

Runge retired this past summer from his three roles as chief executive officer, dean and executive vice president, but still works as both the Frank D. and Agnes C. McKay professor in medicinal science, professor of internal medicine and the special adviser to the Michigan Medicine executive vice president for Medical Affairs.\u00a0<\/p>\n

In the wake of Runge\u2019s departure, his former positions as executive chief officer, dean and executive vice president were divided into two separate leadership roles. Dr. David Miller now serves as the chief executive officer of Michigan Medicine and executive vice president for medical affairs, while the deanship is held by Dr. Thomas Wang. Neither Miller nor Wang serve on external corporate company boards.<\/p>\n

In an interview with The Daily, a tenured Michigan Medicine professor said the decision to separate these leadership roles reflects internal tensions within the Michigan Medicine administration. The professor requested anonymity, citing fears of professional retaliation.\u00a0<\/p>\n

\u201cOne thing that\u2019s being done right away is that the dean and CEO positions are once again being separated,\u201d he said. \u201cI think that that\u2019s a reflection of the sense that too much power was concentrated in one person who didn\u2019t exercise it well.\u201d<\/p>\n

The professor contended that Runge\u2019s external financial relationship with Lilly failed to adhere to the ethos Runge himself expected of Michigan Medicine researchers.<\/p>\n

\u201cHere is an instance where it doesn\u2019t appear that the same rules apply to the dean as to the general faculty, and the dean is far afield from the behavior of similar officers in peer institutions,\u201d he said. \u201cI think that negatively reflects on the institution, and within the institution, creates a sense that the leadership believes that they\u2019re above the rules of the faculty.\u201d<\/p>\n

Focal Point Co-Managing Editor Anna McLean and Focal Point reporters Elizabeth Rozeboom and Elizabeth Foley can be reached at\u00a0agmclean@umich.edu<\/a>, elizaroz@umich.edu<\/a> and elfoley@umich.edu<\/a>.<\/p>\n

All data referenced in this story can be found here<\/a>.<\/p>\n

If you are a survivor on campus who\u2019s faced challenges in reporting, if you\u2019ve faced discrimination or if you have information on any issue relevant to Ann Arbor or the University of Michigan, please consider sending us your story. You can reach us at\u00a0tipline@michigandaily.com<\/a>. This is a private tip line viewable by a small team of reporters committed to this work.<\/p>\n

\n\tRelated articles<\/p>\n","protected":false},"excerpt":{"rendered":"Over a decade marked by a pandemic and nationwide cuts to health care funding, Marschall S. Runge led…\n","protected":false},"author":2,"featured_media":474747,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59],"tags":[97,252,253],"class_list":["post-474746","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-care","tag-health","tag-health-care","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/474746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=474746"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/474746\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/474747"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=474746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=474746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=474746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}